文献速递银屑病与炎症性皮肤病

银屑病患者循环APOA-1与动脉粥样硬化起始及进展的关系

The Relationship between Circulating APOA-1 and Atherosclerosis Initiation and Progression in Psoriasis.
PubMed 文献 · J Invest Dermatol · 2023-04-22

本研究在310例基线、124例4年随访的银屑病患者中,探讨APOA-1、胆固醇流出能力与冠状动脉非钙化斑块负荷(NCB)的关系。APOA-1最低四分位与心血管代谢标志物及更高NCB相关(P < 0.001),且低APOA-1四分位4年后NCB更高(β = -0.36,P = 0.02)。APOA-1每降低10单位,4年NCB进展增加16%(OR = 0.83,95%CI = 0.70-0.99,P = 0.04)。

要点

  • APOA-1最低四分位与胰岛素、HOMA-IR、胆固醇流出能力及更高NCB相关(P < 0.001)。
  • 低APOA-1四分位患者4年后NCB更高(β = -0.36,P = 0.02)。
  • APOA-1每降低10单位,4年NCB进展增加16%(OR = 0.83,95%CI = 0.70-0.99,P = 0.04)。

核心结论

  • 低APOA-1除与心血管代谢疾病相关外,还与随时间增加的NCB相关,提示其可能有助于识别心血管病高风险人群。

研究设计与样本

  • 连续纳入的银屑病患者在基线(n = 310)和4年时(n = 124)接受冠状动脉计算机断层扫描血管造影以量化NCB(Medis QAngio,荷兰莱顿),并检测心血管代谢生物标志物。

主要发现

  • APOA-1最低四分位与心血管代谢血液标志物(胰岛素、胰岛素抵抗稳态模型评估、胆固醇流出能力)及更高NCB相关(P < 0.001)。
  • 在完全校正模型中,低APOA-1四分位者4年时NCB更高(β = -0.36,P = 0.02)。
  • APOA-1每降低10单位与4年NCB进展增加16%相关(OR = 0.83,95%CI = 0.70-0.99,P = 0.04)。

关键数值与推荐

  • APOA-1最低四分位与更高NCB相关(P < 0.001)。
  • 低APOA-1四分位者4年NCB的β = -0.36,P = 0.02。
  • APOA-1每降低10单位,4年NCB进展的OR = 0.83,95%CI = 0.70-0.99,P = 0.04。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

APOA-1 is central to the high-density lipoprotein function of reverse cholesterol transport measured by cholesterol efflux capacity. Psoriasis is a systemic inflammatory disease associated with poor cholesterol efflux capacity and accelerated noncalcified coronary burden (NCB) as measured by coronary computed tomographic angiography. In this study, we characterized the relationship between APOA-1, cholesterol efflux capacity, and progression of NCB over 4 years. Consecutively recruited participants with psoriasis underwent coronary computed tomographic angiography for NCB quantification (Medis QAngio, Leiden, The Netherlands) at baseline (n = 310) and at four years (n = 124). Blood was assessed for cardiometabolic biomarkers. The lowest quartile of APOA-1 was associated with cardiometabolic blood markers (insulin, homeostatic model assessment for insulin resistance, and cholesterol efflux capacity) and higher NCB (P < 0.001). The low APOA-1 quartile had higher NCB at 4 years (β = -0.36, P = 0.02) in fully adjusted models. Finally, a 10-unit decrease of APOA-1 was associated with a 16% increase in NCB progression over 4 years (OR = 0.83, 95% confidence interval = 0.70-0.99, P = 0.04). In addition to being associated with cardiometabolic disease, low APOA-1 was associated with more NCB over time. These findings show that low APOA-1 is correlated with initiation and progression of coronary artery disease and may have clinical utility in identifying high-risk populations for development of cardiovascular disease.

来源:J Invest Dermatol,查看原文。版权归原作者所有。

引用

  1. Teague HL, Li H, Berg AR, et al. The Relationship between Circulating APOA-1 and Atherosclerosis Initiation and Progression in Psoriasis. J Invest Dermatol. 2023. PMID: 37088280. doi:10.1016/j.jid.2023.01.044

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。